Not losing weight on retatrutide can be disheartening, particularly when expectations are high following promising clinical trial data. Retatrutide is an investigational triple receptor agonist — targeting GLP-1, GIP, and glucagon receptors — that remains unlicensed by the MHRA and EMA for routine use in the UK. Access is currently limited to approved clinical trials. If progress has stalled, the reasons are often multifactorial, spanning dose titration stages, underlying medical conditions, and lifestyle factors. This article explores the most common causes of a weight loss plateau on retatrutide and outlines practical, evidence-based steps to take in partnership with your clinical team.

Why You May Not Be Losing Weight on Retatrutide

Weight loss plateaus on retatrutide are common, particularly during dose titration, and reflect complex metabolic adaptations rather than necessarily indicating treatment failure.

Retatrutide is an investigational triple receptor agonist that has shown considerable promise in clinical trials for weight management. However, if you are not losing weight on retatrutide, it is important to understand that this experience is not uncommon, particularly in the early stages of treatment or during dose titration phases.

Weight loss with any pharmacological intervention is rarely linear. Many people experience an initial plateau — a period where the scales do not move despite the medication being active in the body. This can be frustrating, but it does not necessarily mean the treatment is failing. The body undergoes complex metabolic adaptations in response to caloric restriction and hormonal changes, which can temporarily stall progress.

It is important to note that retatrutide is not licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for routine clinical use in the UK. In the UK, access to retatrutide is generally limited to approved clinical trials. If you believe you are obtaining retatrutide outside of a formal clinical trial — for example, from an unregulated or overseas source — please stop and speak to your GP immediately, as the safety and quality of such products cannot be guaranteed.

If you are participating in an approved clinical trial and are not seeing expected results, your trial team or clinical investigator should be your first point of contact. Understanding the reasons behind a lack of progress is the first step towards addressing them effectively.

How Retatrutide Works and What to Expect

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors to suppress appetite and increase energy expenditure; meaningful weight loss typically takes time, especially during dose escalation.

Retatrutide works by simultaneously activating three key hormone receptors involved in appetite regulation and energy metabolism:

• GLP-1 (glucagon-like peptide-1) receptors — reducing appetite and slowing gastric emptying

• GIP (glucose-dependent insulinotropic polypeptide) receptors — thought to enhance insulin secretion and potentially support fat metabolism, though the precise contribution in humans is still being investigated

• Glucagon receptors — hypothesised to increase energy expenditure and promote fat breakdown in the liver, based on preclinical and early clinical data

This triple mechanism of action is designed to produce more substantial and sustained weight loss compared to single or dual receptor agonists. In a Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants receiving higher doses of retatrutide achieved mean weight reductions of approximately 17–24% of body weight over 48 weeks. These findings are promising, though the drug remains under investigation and larger Phase 3 trials are ongoing.

Meaningful weight loss typically takes time to manifest. During the dose escalation period — which is used to minimise gastrointestinal side effects such as nausea, vomiting, and diarrhoea — the full therapeutic dose may not yet be reached. Dose escalation schedules vary by trial protocol and should not be assumed to follow a standard regimen. Patients should therefore not expect dramatic results immediately.

As with other incretin-based therapies, there are potential class-related risks to be aware of, including gallbladder disease and, rarely, pancreatitis. Seek urgent medical attention — call 999 or 111, or go to A&E — if you experience severe or persistent abdominal pain (particularly pain radiating to the back), are unable to keep fluids down, or show signs of dehydration. These symptoms require prompt clinical assessment.

If you experience any suspected side effects, please report them via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk), which helps monitor the safety of medicines and medical devices in the UK.

Medical Reasons That Can Slow Weight Loss Progress

Conditions such as hypothyroidism, PCOS, Cushing's syndrome, and medications including antipsychotics or corticosteroids can significantly blunt weight loss even when retatrutide is active.

Several underlying medical conditions can impair weight loss, even when an effective medication such as retatrutide is being used. It is important that these are identified and managed appropriately, as they may significantly blunt the medication's effectiveness.

Common medical factors include:

• Hypothyroidism — an underactive thyroid reduces metabolic rate and can make weight loss considerably more difficult. In line with NICE NG145 (Thyroid disease: assessment and management), thyroid function testing (TSH, and free T4 if indicated) is appropriate when clinical features suggest thyroid dysfunction — such as fatigue, cold intolerance, constipation, or unexplained weight gain — rather than as a routine screen for all patients struggling to lose weight.

• Polycystic ovary syndrome (PCOS) — associated with insulin resistance and hormonal imbalances that can hinder fat loss, particularly in women of reproductive age. NICE CKS guidance on PCOS provides further detail on assessment and management.

• Type 2 diabetes — insulin resistance and certain diabetes medications (such as sulphonylureas or insulin itself) can counteract weight loss efforts, as noted in NICE NG28 (Type 2 diabetes in adults: management).

• Cushing's syndrome — excess cortisol production promotes fat accumulation, particularly around the abdomen. If clinical features suggest Cushing's syndrome (such as central weight gain, easy bruising, stretch marks, or proximal muscle weakness), referral to an endocrinologist is advisable.

• Depression and other mental health conditions — these can affect motivation, eating behaviours, and sleep, all of which influence body weight.

Certain medicines are also known to cause weight gain or impede weight loss. According to the British National Formulary (BNF) and NICE guidance, these include some antidepressants (particularly mirtazapine and amitriptyline), antipsychotics, corticosteroids, insulin, sulphonylureas, and some beta-blockers. If you are taking any of these, discuss with your GP or prescriber whether alternatives exist. Addressing these underlying factors is essential before concluding that retatrutide is ineffective.

Lifestyle Factors That May Affect Your Results

Diet quality, physical activity, sleep, stress, and alcohol consumption all materially affect weight loss outcomes and should be optimised alongside retatrutide treatment.

Even with a potent pharmacological agent like retatrutide, lifestyle factors remain critically important determinants of weight loss success. Medication is most effective when used as part of a comprehensive approach that includes dietary modification, physical activity, and behavioural support.

Key lifestyle considerations include:

• Dietary intake — retatrutide reduces appetite, but it does not eliminate the impact of calorie-dense foods. Consuming high amounts of ultra-processed foods, sugary drinks, or alcohol can offset the caloric deficit the medication helps to create. The NHS Eatwell Guide provides practical, evidence-based advice on a balanced dietary pattern, including plenty of vegetables, lean protein, wholegrains, and healthy fats.

• Physical activity — regular movement supports weight loss and helps preserve lean muscle mass. The UK Chief Medical Officers' Physical Activity Guidelines recommend that adults aim for at least 150 minutes of moderate-intensity aerobic activity per week, alongside muscle-strengthening activities on at least 2 days per week. Both aerobic exercise and resistance training contribute to overall energy expenditure and metabolic health.

• Sleep quality — poor sleep is strongly associated with increased hunger hormones (ghrelin) and reduced satiety signals (leptin), which can undermine appetite suppression from the medication.

• Stress management — chronic stress elevates cortisol levels, which promotes fat storage and can trigger emotional eating behaviours.

• Alcohol consumption — alcohol is calorie-dense and can stimulate appetite, counteracting the appetite-suppressing effects of retatrutide.

Honest self-reflection about these factors, ideally with the support of a dietitian or health coach, can reveal modifiable behaviours that, once addressed, may reinvigorate weight loss progress.

When to Speak to Your Doctor or Prescriber

Consult your trial team if you have no meaningful weight loss on a stable dose, experience persistent side effects, or develop new symptoms; seek urgent care for severe abdominal pain or dehydration.

Knowing when to seek professional guidance is an important aspect of safe and effective weight management. Because retatrutide is investigational, any decisions about continuing, adjusting, or stopping treatment should be made in close collaboration with your trial team or prescriber, in accordance with your trial protocol and individual clinical circumstances — not based on a fixed timeframe or weight loss threshold.

You should seek advice from your trial team or prescriber if:

• You have been on a stable dose for a sustained period with no meaningful weight loss, as defined by your trial protocol or clinical team

• You are experiencing persistent side effects such as ongoing nausea, vomiting, abdominal discomfort, or changes in bowel habits that are affecting your quality of life or nutritional intake

• You notice unexplained weight gain despite adherence to the treatment programme

• You develop new symptoms that may suggest an underlying medical condition, such as fatigue, cold intolerance, irregular periods, or mood changes

• You are struggling with adherence due to side effects or other concerns — your prescriber may be able to adjust the dose or offer additional support

Seek urgent medical attention — call 999 or 111, or go to A&E — if you experience:

• Severe or persistent abdominal pain, especially if it radiates to the back (which may indicate pancreatitis or gallbladder disease)

• Inability to keep fluids down, or signs of dehydration (such as dizziness, dark urine, or feeling faint)

It is also important to attend all scheduled follow-up appointments as part of your treatment programme. These reviews allow your clinical team to monitor progress, assess tolerability, and make evidence-informed adjustments. Do not discontinue retatrutide without medical advice, as abrupt cessation may affect your overall management plan.

If you experience any suspected adverse reactions, please report them via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Next Steps If Retatrutide Is Not Working for You

Options include dose optimisation under supervision, multidisciplinary review, NICE-approved alternatives such as semaglutide or tirzepatide, or referral to NHS Tier 3/4 weight management services or bariatric surgery.

If, after a thorough review of medical, lifestyle, and adherence factors, retatrutide still does not appear to be producing adequate weight loss, there are several constructive next steps to consider in partnership with your healthcare team.

Firstly, your prescriber or trial team may consider dose optimisation. Retatrutide is administered in escalating doses according to trial protocol, and some individuals may require higher doses to achieve a meaningful therapeutic response. This should only be done under medical supervision, with careful monitoring for side effects.

Secondly, a multidisciplinary review may be beneficial. This could involve input from an endocrinologist, dietitian, psychologist, or specialist obesity service. In the UK, NHS Tier 3 weight management services offer structured, multi-component programmes for individuals with complex obesity-related needs, typically accessed via GP referral. For those who meet criteria, Tier 4 services provide access to bariatric surgery pathways, in line with NICE CG189 (Obesity: identification, assessment and management) and NHS England commissioning specifications.

Thirdly, if retatrutide is genuinely not effective for you, your clinician may discuss alternative pharmacological options. In the UK, NICE-approved treatments for weight management currently include orlistat, semaglutide 2.4 mg (Wegovy; NICE TA875) and tirzepatide (Mounjaro; NICE TA, 2024/2025) for eligible patients. Each works through different mechanisms and may suit different individuals. Eligibility criteria and commissioning arrangements vary, so discuss with your GP or specialist.

Finally, for those with severe obesity (BMI ≥40 kg/m², or ≥35 kg/m² with significant comorbidities) who have not responded to medical management, bariatric surgery remains a highly effective option and should be discussed with a specialist. It is worth noting that lower BMI thresholds may be appropriate for eligibility in some ethnic groups, in line with current NICE and NHS England guidance. Whatever the next step, the goal is to find a safe, sustainable, and personalised approach to weight management that supports your long-term health.

Frequently Asked Questions